報價延遲最少15分鐘:2026/04/21 19:46 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.72 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.12/--
|
|
企業價值
84.05M
|
| 資產負債 |
|
每股賬面淨值
2.99
|
| 現金流量 |
|
現金流量率
0.03
|
| 損益表 |
|
收益
27.64M
|
|
每股收益
1.73
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against theprincipal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line. |
